Richard is a seasoned drug discovery executive with a background spanning computational chemistry and global business development. He previously served as CBO of Exscientia, overseeing its Nasdaq IPO, major collaborations with BMS, Sanofi and Merck Darmstadt, and finally the merger with Recursion in 2024. At HAYA Therapeutics, Richard drives business strategy development by leveraging HAYA’s pioneering Regulatory Genome platform to create high-value biopharma partnerships, accelerate company growth, and secure life sciences funding.